Evidence map›Paper›PMID 30049285›Full record

ArticleCardiovascular diabetology2018

Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice.

Νarjes Nasiri-Ansari, Georgios K Dimitriadis, Georgios Agrogiannis, Despoina Perrea, Ioannis D Kostakis, Gregory Kaltsas, Athanasios G Papavassiliou, Harpal S Randeva, Eva Kassi

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardiovascular diabetology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed, 2 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 2 syntheses or guidelines pooled it, 160 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Νarjes Nasiri-AnsariDepartment of Biological Chemistry, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Georgios K DimitriadisDivision of Translational and Experimental Medicine-Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK.
Georgios AgrogiannisLaboratory of Pathological Anatomy, Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Despoina PerreaLaboratory for Experimental Surgery and Surgical Research "N.S. Christeas", Medical School, National and Kapodistrian University of Athens, Athens, Greece.
Ioannis D KostakisSecond Department of Propedeutic Surgery, National and Kapodistrian University of Athens, Medical School, 'Laiko' General Hospital, Athens, Greece.
Gregory KaltsasHuman Metabolism Research Unit, WISDEM Centre, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, CV2 2DX, UK.
Athanasios G PapavassiliouDepartment of Biological Chemistry, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Harpal S RandevaDivision of Translational and Experimental Medicine-Metabolic and Vascular Health, Warwick Medical School, University of Warwick, Coventry, CV4 7AL, UK. harpal.randeva@warwick.ac.uk.
Eva KassiDepartment of Biological Chemistry, National and Kapodistrian University of Athens Medical School, Athens, Greece. ekassi@med.uoa.gr.
National and Kapodistrian University of Athens · GRUniversity Hospitals Coventry and Warwickshire NHS Trust · GBImperial College London · GBLaiko General Hospital of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSodium glucose co-transporter2 inhibitors reduce the incidence of cardiovascular events in patients with type 2 diabetes mellitus based on the results of recent cardiovascular outcome studies. Herein, we investigated the effects of long-term treatment with canagliflozin on biochemical and immunohistochemical markers related to atherosclerosis and atherosclerosis development in the aorta of apolipoprotein E knockout (Apo-E

methodsAt the age of 5 weeks, mice were switched from normal to a high-fat diet. After 5 weeks, Apo-E

resultsCanagliflozin-group mice had lower total-cholesterol, triglycerides and glucose levels (P < 0.01), while heart rate was significantly lower (P < 0.05). Histomorphometry revealed that one in seven Cana-group mice versus four in six control mice developed atheromatosis, while aortic root plaque was significantly less, and collagen was 1.6 times more intense in canagliflozin-group suggesting increased plaque stability. Immunohistochemistry revealed that MCP-1 was significantly less expressed (P < 0.05) in the aortic root of canagliflozin-group while reduced expression of a-actin and CD68 was not reaching significance (P = 0.15). VCAM-1 and MCP-1 mRNA levels were lower (P = 0.02 and P = 0.07, respectively), while TIMP-1/MMP-2 ratio expression was higher in canagliflozin-group approaching statistical significance (P = 0.07).

conclusionsCanagliflozin attenuates the progression of atherosclerosis, reducing (1) hyperlipidemia and hyperglycemia, and (2) inflammatory process, by lowering the expression of inflammatory molecules such as MCP-1 and VCAM-1. Moreover, canagliflozin was found to increase the atherosclerotic plaque stability via increasing TIMP-1/MMP-2 ratio expression.

Indexed as

AnimalsAortaAortic DiseasesAtherosclerosisBlood GlucoseCanagliflozinCollagenCollagenasesDisease Models, AnimalDisease ProgressionInflammationInflammation MediatorsLipidsMaleMice, Inbred C57BLMice, Knockout, ApoEBlood GlucoseCanagliflozinCollagenCollagenasesInflammation MediatorsLipidsSodium-Glucose Transporter 2 InhibitorsTissue Inhibitor of MetalloproteinasesAPOE knockout miceAtherosclerosisCanagliflozinInflammationSGLT2i

Identifiers

PMID30049285
PMCPMC6063004
OpenAlexW2884101530

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.